{
    "title": "AstraZeneca shares fall 8% following disappointing results from trials of its new lung cancer drug",
    "url": "https://www.dailymail.co.uk/money/markets/article-12260309/AstraZeneca-shares-hit-lung-cancer-drug-setback.html",
    "date": "2023-07-03",
    "keywords": [
        "drug",
        "cancer",
        "trial",
        "lung",
        "share",
        "account",
        "fund",
        "number",
        "firm",
        "treatment",
        "side",
        "money",
        "diy",
        "deruxtecan",
        "method",
        "investment",
        "fee",
        "hit",
        "hopedthe",
        "pharma",
        "giant",
        "datopotamab",
        "deruxtecangrade",
        "safety",
        "news",
        "cent",
        "fact",
        "group",
        "blow",
        "astrazenecas",
        "sankyo",
        "treatmentbut",
        "broker",
        "stifel",
        "company",
        "experience",
        "outcomesit",
        "absence",
        "magnitude",
        "benefit",
        "brummer",
        "price",
        "gouging",
        "carillion",
        "finance",
        "chief",
        "boardroom",
        "ban",
        "profiteering",
        "interest",
        "member",
        "article",
        "galbraith",
        "head",
        "oncology",
        "research",
        "evidence",
        "role",
        "gather",
        "survival",
        "resultsdatopotamab",
        "chemotherapy",
        "chemo",
        "body",
        "cellsin",
        "astrazeneca",
        "progression",
        "disease",
        "standard",
        "docetaxel",
        "capital",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}